You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 137 No. 4, April 1977 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Insulin Receptor Status in Disease States of Man

Robert S. Bar, MD; Jesse Roth, MD

Arch Intern Med. 1977;137(4):474-481.


Abstract

When insulin or any peptide hormone binds to its receptor on the surface of a target cell, it initiates a series of biochemical steps that ultimately lead to the characteristic action of the hormone. The strength of the signal generated by the hormone depends equally on the hormone concentration, the receptor concentration, and the receptor affinity. Not only do hormone concentrations change rapidly and widely in vivo but so do receptor concentration and affinity. In hormone resistant states, any step in the biochemical pathway of hormone action at the target cell may be involved. Studies of insulin receptors in people indicate that the insulin receptor is altered in many common disorders such as obesity and diabetes, as well as in rare disorders such as extreme insulin resistance due to circulating antibodies directed at the insulin receptor itself. By responding to both intracellular and extracellular events, the insulin receptor is, therefore, a major site for the regulation of target cell responsiveness in vivo.

(Arch Intern Med 137:474-481, 1977)



Author Affiliations

From the Diabetes Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Md.


Footnotes

Reprint requests to Diabetes Branch, Bldg 10, Room 85-243, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, MD 20014 (Dr Roth).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identification and Treatment of Metabolic Abnormalities in Patients With Vertigo
Lehrer et al.
Arch Intern Med 1986;146:1497-1500.
ABSTRACT  

Using Research in Practice: Mechanisms of Drug Tolerance
Fuller
West J Nurs Res 1982;4:113-118.
 

Blood-brain glucose transfer: repression in chronic hyperglycemia
Gjedde and Crone
Science 1981;214:456-457.
ABSTRACT  

Cutaneous Manifestations of Leprechaunism
Roth et al.
Arch Dermatol 1981;117:531-535.
ABSTRACT  

Principles of Membrane Receptor Physiology and Their Application to Clinical Medicine
POLLET and LEVEY
ANN INTERN MED 1980;92:663-680.
ABSTRACT  

Endocrinology and Metabolism: An Annotated Bibliography of Recent Literature: References to Journal Articles and Other Papers
ENDOCRINOLOGY AND METABOLISM COMMITTEE
ANN INTERN MED 1979;90:726-731.
ABSTRACT  

Diabetes: New Insights and Old Concepts
Felig
Arch Intern Med 1977;137:569-570.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1977 American Medical Association. All Rights Reserved.